Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

BACKGROUND: This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib as a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC). METHODS: In this open-label, multicenter study, previously treated Asi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Bi, Feng, Jin, Jie, Cheng, Ying, Guo, Jun, Ren, Xiubao, Huang, Yiran, Tarazi, Jamal, Tang, Jie, Chen, Connie, Kim, Sinil, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467642/
https://www.ncbi.nlm.nih.gov/pubmed/26089686
http://dx.doi.org/10.2147/OTT.S83302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467642/
https://www.ncbi.nlm.nih.gov/pubmed/26089686
http://dx.doi.org/10.2147/OTT.S83302

Ejemplares similares